Palvella director plans $4.1M stock sale

Palvella Therapeutics, Inc. (PVLA) director George M. Jenkins filed a notice of proposed sale of 27,500 shares of common stock under Rule 144.

Available on EDGAR 09/11/2026 - 04:35 PM EDT Accepted by SEC EDGAR 09/11/2026 - 04:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. (PVLA) director George M. Jenkins filed a notice of proposed sale of 27,500 shares of common stock under Rule 144. The shares were originally acquired on March 6, 2017 through a private investment for cash and are expected to be sold through Piper Sandler on NASDAQ.

Key Figures

Shares proposed for sale: 27,500 shares Aggregate market value of proposed sale: $4,135,725.00 Shares outstanding: 14,408,407 shares +2 more

5 metrics

Shares proposed for sale 27,500 shares Common stock covered by George M. Jenkins’ Rule 144 notice

Aggregate market value of proposed sale $4,135,725.00 Value listed for 27,500 Palvella Therapeutics common shares

Shares outstanding 14,408,407 shares Palvella Therapeutics common stock outstanding as reported in the Form 144

Acquisition date of shares March 6, 2017 Date the shares to be sold were acquired in a private investment

Planned sale date reference September 11, 2026 Approximate date of sale listed for the Rule 144 transaction

Key Terms

Rule 144, private investment, attorney-in-fact, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

private investment financial

"Common Stock | 03/06/2017 | Private Investment | George Jenkins"

attorney-in-fact regulatory

"as attorney-in-fact for George Jenkins"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

aggregate market value financial

"Common Stock | Piper Sandler ... | 27500 | 4135725.00 | 14408407"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Palvella Therapeutics (PVLA) disclose in this Form 144?

The filing states that director George M. Jenkins plans a potential sale of 27,500 shares of Palvella Therapeutics common stock under Rule 144, with Piper Sandler as broker and sales expected to occur on NASDAQ.

How many PVLA shares are covered by George Jenkins’ planned Rule 144 sale?

The notice covers a proposed sale of 27,500 shares of Palvella Therapeutics, Inc. common stock. This is a maximum amount indicated for potential sale under Rule 144 in the current filing.

What is the stated market value of the PVLA shares in this Form 144?

The Form 144 lists an aggregate market value of $4,135,725.00 for the 27,500 common shares of Palvella Therapeutics covered by the proposed Rule 144 sale.

When and how did George Jenkins acquire the PVLA shares to be sold?

The shares to be sold were acquired on March 6, 2017 in a private investment, with the Form 144 indicating the form of payment as cash.

How many Palvella Therapeutics (PVLA) shares are reported outstanding in the Form 144?

The Form 144 reports 14,408,407 shares of Palvella Therapeutics common stock outstanding, providing context for the 27,500 shares covered by the proposed sale notice.

Which broker is handling the proposed PVLA share sale under Rule 144?

The proposed sale of 27,500 Palvella Therapeutics common shares is listed as being through Piper Sandler, with the shares expected to be sold on NASDAQ according to the Form 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001271081
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PALVELLA THERAPEUTICS, INC.
SEC File Number	001-37471
Address of Issuer	353 W. LANCASTER AVENUE SUITE 200 WAYNE PENNSYLVANIA 19087
Phone	(484) 253-1461
Name of Person for Whose Account the Securities are To Be Sold	JENKINS GEORGE M
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Piper Sandler 350 North 5th Street, Suite 1000 Minneapolis MN 55401	27500	4135725.00	14408407	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/06/2017	Private Investment	George Jenkins			27500	03/06/2017	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Will Britton, a duly authorized representative of Piper Sandler & Co Corporate & Venture Services FA, as attorney-in-fact for George Jenkins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)